Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $18.81M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 1.6% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.81M— QoQ
Last fiscal yearDec 2025
$18.39M— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
18.39M USD
Year-over-year change
—

Short-term Debt vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's Mar 2026 short-term debt of $18.81M is the 3rd highest of the 7 companies compared; the peer median is $4.07M.
  • Short-term debt amounts to 1.6% of total assets for AGIO, versus a peer median of 0.8%.
AGIO Competitors Peer median
Short-term Debt for AGIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RAREUltragenyx Pharmaceutical Inc.Mar 2026$72M ——5.6%
PTCTPTC Therapeutics, Inc.Jun 2026$55.45M —+99.1%1.7%
AGIOAgios Pharmaceuticals, Inc.Mar 2026$18.81M ——1.6%
PHARPharming Group N.V.Mar 2026$8.15M +78.8%+44.5%1.7%
MIRMMirum Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
IRONDisc Medicine, Inc.Sep 2026$0 ——0.0%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
Peer median (excluding AGIO) $4.07M+78.8%+71.8%0.8%

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents203.13M139.26M88.21M76.25M89.13M
Short-term Investments816.89M643.86M688.72M817.46M765.3M
Net Receivables4.38M2.21M2.81M4.11M10.58M
Inventory08.49M19.08M27.62M32.92M
Other Current Assets038.96M35.02M40.17M44.13M
Total Current Assets1.06B832.77M833.84M965.6M942.05M
Property, Plant & Equipment (Net)104.23M88.12M69.79M54.55M41.23M
Goodwill00000
Intangible Assets00000
Long-term Investments266.38M313.87M29.44M638.32M310.01M
Tax Assets00000
Other Non-current Assets2.9M3.96M4.06M4.72M3.93M
Total Non-current Assets373.51M405.95M103.28M697.6M355.17M
Total Assets1.44B1.24B937.12M1.66B1.3B
Account Payables16.7M18.62M9.78M16.64M18.36M
Short-term Debt000018.39M
Tax Payables000871K0
Deferred Revenue00000
Other Current Liabilities19.82M12.25M23.23M29.94M18.2M
Total Current Liabilities59.83M62.63M67.96M81.16M82.21M
Long-term Debt000021.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities03.28M1.16M880K(21.73M)
Total Non-current Liabilities85.94M75.28M58.14M41.09M21.91M
Total Liabilities145.76M137.9M126.1M122.24M104.11M
Common Stock71K71K72K73K75K
Retained Earnings(238.76M)(470.56M)(822.65M)(148.92M)(561.71M)
Accumulated OCI(1.2M)(12.54M)(441K)(1.52M)2.19M
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.29B1.1B811.02M1.54B1.19B
Total Debt97.09M85.66M72M56.99M62.02M
Net Debt(106.03M)(53.6M)(16.21M)(19.26M)(27.11M)

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.